For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

A letter to the US public on the AMA website, signed by 75+ medical societies, stresses the vital importance of influenza, RSV, and COVID-19 vaccines.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Nearly three-quarters of infants were immunized against respiratory syncytial virus through maternal vaccination or ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

1 Introduction. Respiratory syncytial virus (RSV) is the main cause of hospitalization for lower respiratory tract infections in infants and young children worldwide and is a leading cause of ...

1. Boller MJ, Ward LR, Gibbins KJ, Valent AM, Bayer LL. Uptake of Respiratory Syncytial Virus Protection in the Inaugural Prenatal Vaccination Season: A Tertiary Referral Center Experience. Abstract.

Every year, millions of people worldwide are affected by a virus that often goes unnoticed –Respiratory Syncytial Virus (RSV). Despite its widespread prevalence, many people remain unaware of what RSV ...